Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Neurodegenerative Diseases Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 NMDA
  • 1.3.3 SSRIs
  • 1.3.4 Dopamine Inhibitors
• 1.4 Market Segment by Application
  • 1.4.1 Global Neurodegenerative Diseases Market Share by Application (2019-2025)
  • 1.4.2 Parkinson’s disease
  • 1.4.3 Huntington disease
  • 1.4.4 Amyotrophic Lateral Sclerosis
  • 1.4.5 Alzheimer’s disease
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Neurodegenerative Diseases Market Size
  • 2.1.1 Global Neurodegenerative Diseases Revenue 2014-2025
  • 2.1.2 Global Neurodegenerative Diseases Sales 2014-2025
• 2.2 Neurodegenerative Diseases Growth Rate by Regions
  • 2.2.1 Global Neurodegenerative Diseases Sales by Regions 2014-2019
  • 2.2.2 Global Neurodegenerative Diseases Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Neurodegenerative Diseases Sales by Manufacturers
  • 3.1.1 Neurodegenerative Diseases Sales by Manufacturers 2014-2019
  • 3.1.2 Neurodegenerative Diseases Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Neurodegenerative Diseases Revenue by Manufacturers (2014-2019)
  • 3.2.2 Neurodegenerative Diseases Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
• 3.3 Neurodegenerative Diseases Price by Manufacturers
• 3.4 Key Manufacturers Neurodegenerative Diseases Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Neurodegenerative Diseases Market
• 3.6 Key Manufacturers Neurodegenerative Diseases Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 NMDA Sales and Revenue (2014-2019)
  • 4.1.2 SSRIs Sales and Revenue (2014-2019)
  • 4.1.3 Dopamine Inhibitors Sales and Revenue (2014-2019)
• 4.2 Global Neurodegenerative Diseases Sales Market Share by Type
• 4.3 Global Neurodegenerative Diseases Revenue Market Share by Type
• 4.4 Neurodegenerative Diseases Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Neurodegenerative Diseases Sales by Application

6 United States

• 6.1 United States Neurodegenerative Diseases Breakdown Data by Company
• 6.2 United States Neurodegenerative Diseases Breakdown Data by Type
• 6.3 United States Neurodegenerative Diseases Breakdown Data by Application

7 European Union

• 7.1 European Union Neurodegenerative Diseases Breakdown Data by Company
• 7.2 European Union Neurodegenerative Diseases Breakdown Data by Type
• 7.3 European Union Neurodegenerative Diseases Breakdown Data by Application

8 China

• 8.1 China Neurodegenerative Diseases Breakdown Data by Company
• 8.2 China Neurodegenerative Diseases Breakdown Data by Type
• 8.3 China Neurodegenerative Diseases Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Neurodegenerative Diseases Breakdown Data by Company
• 9.2 Rest of World Neurodegenerative Diseases Breakdown Data by Type
• 9.3 Rest of World Neurodegenerative Diseases Breakdown Data by Application
• 9.4 Rest of World Neurodegenerative Diseases Breakdown Data by Countries
  • 9.4.1 Rest of World Neurodegenerative Diseases Sales by Countries
  • 9.4.2 Rest of World Neurodegenerative Diseases Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Novartis
  • 10.1.1 Novartis Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.1.4 Neurodegenerative Diseases Product Introduction
  • 10.1.5 Novartis Recent Development
• 10.2 Merck Serono
  • 10.2.1 Merck Serono Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.2.4 Neurodegenerative Diseases Product Introduction
  • 10.2.5 Merck Serono Recent Development
• 10.3 Teva Pharmaceutical
  • 10.3.1 Teva Pharmaceutical Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.3.4 Neurodegenerative Diseases Product Introduction
  • 10.3.5 Teva Pharmaceutical Recent Development
• 10.4 UCB
  • 10.4.1 UCB Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.4.4 Neurodegenerative Diseases Product Introduction
  • 10.4.5 UCB Recent Development
• 10.5 Pfizer
  • 10.5.1 Pfizer Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.5.4 Neurodegenerative Diseases Product Introduction
  • 10.5.5 Pfizer Recent Development
• 10.6 Biogen Idec
  • 10.6.1 Biogen Idec Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.6.4 Neurodegenerative Diseases Product Introduction
  • 10.6.5 Biogen Idec Recent Development
• 10.7 Bayer Schering Pharma AG
  • 10.7.1 Bayer Schering Pharma AG Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.7.4 Neurodegenerative Diseases Product Introduction
  • 10.7.5 Bayer Schering Pharma AG Recent Development
• 10.8 Boehringer Ingelheim
  • 10.8.1 Boehringer Ingelheim Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.8.4 Neurodegenerative Diseases Product Introduction
  • 10.8.5 Boehringer Ingelheim Recent Development
• 10.9 Addex Pharmaceutical
  • 10.9.1 Addex Pharmaceutical Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.9.4 Neurodegenerative Diseases Product Introduction
  • 10.9.5 Addex Pharmaceutical Recent Development
• 10.10 Amarin
  • 10.10.1 Amarin Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Neurodegenerative Diseases
  • 10.10.4 Neurodegenerative Diseases Product Introduction
  • 10.10.5 Amarin Recent Development
• 10.11 AstraZeneca
• 10.12 Asubio Pharmaceutical
• 10.13 Bial
• 10.14 Alector
• 10.15 Yumanity Therapeutics
• 10.16 Eisai
• 10.17 H.Lundbeck A/S
• 10.18 Jiangsu Hansoh Pharmaceutical
• 10.19 Yangtze River Pharmaceutical Group
• 10.20 Chongqing Zein Pharmaceutical

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Neurodegenerative Diseases Sales Channels
  • 11.2.2 Neurodegenerative Diseases Distributors
• 11.3 Neurodegenerative Diseases Customers

12 Market Forecast

• 12.1 Global Neurodegenerative Diseases Sales and Revenue Forecast 2019-2025
• 12.2 Global Neurodegenerative Diseases Sales Forecast by Type
• 12.3 Global Neurodegenerative Diseases Sales Forecast by Application
• 12.4 Neurodegenerative Diseases Forecast by Regions
  • 12.4.1 Global Neurodegenerative Diseases Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Neurodegenerative Diseases Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages.
In 2019, the market size of Neurodegenerative Diseases is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Neurodegenerative Diseases.

This report studies the global market size of Neurodegenerative Diseases, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Neurodegenerative Diseases sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Novartis
Merck Serono
Teva Pharmaceutical
UCB
Pfizer
Biogen Idec
Bayer Schering Pharma AG
Boehringer Ingelheim
Addex Pharmaceutical
Amarin
AstraZeneca
Asubio Pharmaceutical
Bial
Alector
Yumanity Therapeutics
Eisai
H.Lundbeck A/S
Jiangsu Hansoh Pharmaceutical
Yangtze River Pharmaceutical Group
Chongqing Zein Pharmaceutical

Market Segment by Product Type
NMDA
SSRIs
Dopamine Inhibitors

Market Segment by Application
Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Neurodegenerative Diseases status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Neurodegenerative Diseases manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Neurodegenerative Diseases are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025